Please assess the completion status of the following clinical trial:

Trial Title: A Pilot Trial of Curcumin Effects on Cognition in Schizophrenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~1. 18 - 65 years of age~2. English speaking~3. Diagnostic and Statistical Manual- IV diagnosis of schizophrenia or schizoaffective disorder based on Structured Clinical Interview for Diagnostic and Statistical Manual-IV (SCID)~4. Symptomatic stability confirmed by clinical staff in the 8 weeks prior to the study~5. No changes in antipsychotic medication within the last 8 weeks~6. No change in antipsychotic dose in in last 4 weeks.~Exclusion criteria are:~1. Unable to provide informed consent~2. Diagnostic and Statistical Manual-IV (DSM-IV) diagnosis of alcohol/substance dependence~3. Recent history of gastrointestinal bleeding or ulceration~4. Recent history of gallstones and/or bile duct obstruction~5. Significant uncontrolled systemic illness (e.g. chronic renal failure, chronic liver disease, poorly controlled diabetes, poorly controlled congestive heart failure, chronic infectious disease, chronic autoimmune disease)~6. Known intolerance to turmeric, curcumin, or curry~7. Pregnancy or breast-feeding~8. Current use of anti-platelet, anti-coagulant, glucocorticoid, immunosuppressants~9. Daily use of non-steroidal anti-inflammatory use.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Curcumin 1800mg (Type: EXPERIMENTAL): curcumin capsule 600mg taken 3 times per day for 8 weeks
- Placebo (Type: PLACEBO_COMPARATOR): placebo capsule taken 3 times per day for 8 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).